Clinical Course and Outcomes of COVID‐19 in Hematopoietic Cell Transplant Patients: A Regional Report from the Middle East

Fakih, Riad El; Haroon, Alfadil; Alfraih, Feras; Al-Khabori, Murtadha; Alzahrani, Mohsen; Alhuraiji, Ahmad; Hamadah, Abdulaziz; Aljohani, Naif; Alahmari, Bader; Essa, Mohammed F.; Motabi, Ibraheem; Tailor, Imran K; Almaghrabi, Reem S.; Al-Farsi, Khalil; Abosoudah, Ibraheem; Ayas, Mouhab; Elhassan, Tusneem; Suhebeh, Ashraf M.; Ahmed, Syed Osman; Kaloyannidis, Panayotis; Alsaeed, Ahmad; Anezi, Khalid Al; Alamoudi, Sameer; Damlaj, Moussab; Hashmi, Hani Al; Aljurf, Mahmoud

doi:10.2139/ssrn.3790456

Cited by 7 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18,22,25,26,29 Radiological abnormalities on chest imaging, including chest x-ray and CT scans, were seen in 47% patients (95% CI 0.35-0.59, I 2 = 89%, n = 293/615) as reported by 10 studies. 15,17,18,21,22,25,26,29,30,33 Severity of COVID-19 was not defined uniformly by studies included in this meta-analysis. Various definitions used to define COVID-19 severity by included studies are detailed in Tables S2-S3.…”

Section: Resultsmentioning

confidence: 85%

“…15,16,18,20,25,26,28,29,32,33 Hypoxia requiring oxygen was reported in 33% patients (95% CI 0.26-0.42, I 2 = 91%, n = 529/1781). 15,17,18,22,23,[25][26][27][28][29][30][31]33 ICU admission was needed in 29% patients (95% CI 0.17-0.44, I2 = 97%, n = 466/2015), [15][16][17][18][21][22][23][24][25][26][27][28][29][30][31][32][33] and mechanical ventilation was performed in 18% (95% CI 0.12-0.24, I2 = 67%, n = 109/591) 15,16,18,19,21,22,[26][27][28][29]…”

Section: Resultsmentioning

confidence: 99%

“…20,22,31 Active graft-versus-host disease (GVHD) at the time of COVID-19 diagnosis was reported in 21% (95% CI 0.15-0.27, I 2 = 64%, n = 149/701) patients. 17,18,20,22,26,29,31,33 A total of 27 patients had acute GVHD, 17,18,20,29,31,33 and 98 patients has chronic GVHD. 18,29,31,33 Two of the included studies did not specify the type of active GvHD.…”

Section: Resultsmentioning

confidence: 99%

“…29,36,37 patients, consistent with previous literature. 18,20,22,26,28,38,39 Mushtaq et al reported an association of lymphopenia with disease severity and death. 22 Elevated inflammatory markers, including ferritin and CRP, were associated with disease severity and mortality.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis

Shahzad

Chaudhary

Zafar

et al. 2022

Transplant Infectious Dis

View full text Add to dashboard Cite

Background: Hematopoietic stem cell transplant (HSCT) recipients are at increased risk of mortality and morbidity with coronavirus disease 2019 (COVID-19) due to severe immune dysfunction. Methods:A literature search was performed on PubMed, Cochrane, and Clinical trials.gov from the date of inception to 12/08/2021. We identified 19 original studies reporting data on COVID-19 in HSCT recipients after screening 292 articles.Data were extracted following preferred reporting items for systematic reviews and meta-analysis guidelines. Quality evaluation was done using the National Institutes of Health (NIH) quality assessment tool. Inter-study variance was calculated using Der Simonian-Laird Estimator. Pooled analysis was conducted using MetaXL. A randomeffects model was used to estimate the proportions with 95% confidence intervals (CI).Results: Of 6711 patients in 19 studies, 2031 HSCT patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were analyzed. The median age of patients was 56.9 (range 1-81.6) years, and 63% patients were men according to 14 studies. The median time from transplant to SARS-CoV-2 infection for autologous (auto) and allogeneic (allo) HSCT patients was 23.2 (0.33-350.5) months and 16.4 (0.2-292.7) months, respectively. The median follow-up time after COVID-19 diagnosis was 28 (0-262) days. The COVID-19 mortality rate was 19% (95% CI 0.15-0.24, I 2 = 76%, n = 373/2031). The pooled mortality rate was 17% (95% CI 0.12-0.24, I 2 = 78%, n = 147/904) in auto-HSCT patients and 21% (95% CI 0.16-0.25, I 2 = 60%, n = 231/1103) in allo-HSCT patients.Conclusions: HSCT recipients have a high risk of mortality and clinical complications due to COVID-19. There is a need for ongoing vigilance, masks, and social distancing, vaccination, and aggressive management of SARS-CoV-2 infection in HSCT recipients.

show abstract

Section: Resultsmentioning

confidence: 85%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis

Shahzad

Chaudhary

Zafar

et al. 2022

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported on the clinical consequences and outcomes of COVID-19 on HCT patients 15 , 16 and the impact of COVID-19 on HCT centers; however, to our knowledge, there are no studies that have reported on patient reported experiences during the pandemic. Given the unique challenges faced by the HCT population during the COVID-19 pandemic, it is important to understand experiences and perspectives of this patient population.…”

Section: Introductionmentioning

confidence: 99%

Perceptions and Experiences of Hematopoietic Cell Transplantation Patients During the COVID-19 Pandemic

Mohanraj¹,

Elswick²,

Buch³

et al. 2022

Seminars in Oncology Nursing

View full text Add to dashboard Cite

Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis

Carrara

Razzaboni

Azzini

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

Main aim of this systematic review is to quantify the risk and identify predictors of clinical evolution of SARS‐CoV‐2 in hematological patients compared to different control populations. Two independent reviewers screened the literature assessing clinical outcomes of SARS‐CoV‐2 infection in adult patients with active hematological malignancies published up to June 2021. Primary outcome was COVID‐19 related mortality, secondary outcomes were hospital and intensive‐care admission, mechanical ventilation (MV), and thromboembolic events. Variables related to study setting, baseline patients' demographic, comorbidities, underlying hematological disease, ongoing chemotherapy, COVID‐19 presentation, and treatments were extracted. A total of 67 studies including 10,061 hematological patients and 111,143 controls were included. Most of the studies were retrospective cohorts (51 studies, 76%) and only 19 (13%) provided data for a control group. A significant increased risk of clinical progression in the hematological population compared to the controls was found in terms of COVID‐19 related mortality (OR, 2.12; 95% CI, 1.77–2.54), hospitalization (OR, 1.98; 95% CI, 1.15–3.43), intensive‐care admission (OR, 1.77; 95% CI, 1.38–2.26), and MV (OR, 2.17; 95% CI, 1.71–2.75). The risk remained significantly higher in the subgroup analysis comparing hematological patients versus solid cancer. Meta‐regression analysis of uncontrolled studies showed that older age, male sex, and hypertension were significantly related to worse clinical outcomes of COVID‐19 in hematological population. Older age and hypertension were found to be associated also to thromboembolic events. In conclusion, hematological patients have a higher risk of COVID‐19 clinical progression compared to both the general population and to patients with solid cancer.

show abstract

Clinical Course and Outcomes of COVID‐19 in Hematopoietic Cell Transplant Patients: A Regional Report from the Middle East

Cited by 7 publications

References 0 publications

Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis

Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis

Perceptions and Experiences of Hematopoietic Cell Transplantation Patients During the COVID-19 Pandemic

Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis

Contact Info

Product

Resources

About